Antibody Response in People living with HIV Comparing CD4 T-cell Levels more than 200 vs. lower or equal 200 cells/mm3 after mRNA COVID-19 Vaccine Booster
- Conditions
- Antibody responseHIVCovid vaccineCD4 levelimmunogenicityAntibody responseSARS-CoV-2AntiSARS-CoV vaccineHIV/AIDsSurrogate virus neutralization test
- Registration Number
- TCTR20240708002
- Lead Sponsor
- Thai AIDS society
- Brief Summary
In low CD4 group, participants exhibited lower baseline levels of both Anti RBD Ig and sVNT against all variants. In post-booster vaccination with the bivalent COVID-19 vaccine, the lower CD4 group also showed reduced immunogenicity. Higher GMR was observed in low CD4 group
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 74
1. Individuals living with HIV aged 18 years and above
2. on stable antiretroviral regimen for at least three months
3. Received at least two doses of the primary COVID-19 vaccine more than three months prior to enrollment in the study
1. virologic failure, defined as an HIV viral load exceeding 200 copies/mL
2. high-level immunosuppression, such as the use of prednisolone at doses exceeding 20 mg/day
methotrexate at doses exceeding 0.4 mg/kg/week, or previous administration of rituximab or TNF-alpha blockers within the past year
3. active autoimmune disease
4. contraindications for COVID-19 vaccination
5. previous administration of monoclonal antibodies, JAK inhibitors, or convalescent plasma for COVID-19
6. receipt of any other vaccination within 15 days prior to enrollment
7. self-reported history of SARS-CoV-2 infection in the 3 months prior to enrollment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AntiRBDIgG 1 month AU/m
- Secondary Outcome Measures
Name Time Method sVNT 1 month percent